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Summain, The efficacv and modes of action of dibromodulcitol (DBD) and cisplatin (CDDP) were studied in
several model systems. Combination treatments produced a longer survival time in mice bearing P388 solid
lymphomas than either of the drugs alone. In the human metastatic melanoma HT-168 xenograft model the
combined application of DBD and CDDP was also very effective, inducing a reduction in the number and
volume of metastatic nodules. For V79 spheroids. DBD was mainly cytotoxic against the internal, quiescent
cells, whereas cisplatin primarily killed cells in the proliferating, external regions of the spheroids. When
combined, the drugs appeared to act synergistically throughout the spheroids. Studies on plasmid DNA
showed that CDDP primarily generates cross-links, whereas single-strand breaks were dominant after DBD
treatment. Upon using an assay for cleavage by restriction nuclease, antagonistic action of DBD and CDDP in
combination may occur, nevertheless more strand breaks were always observed in these samples. These results
suggest that the efficacy of combined DBD and CDDP is in part a result of 'spatial cooperation' by the drugs
(i e. affecting different cells) and in part the result of DNA damage produced by the combination
treatments.
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Dibromodulcitol (DBD) has been shown to induce altera-
tions in chromatin components. including binding to DNA
(Jeney et al.. 1979; Institons and Tamas. 1983). It is effective
against various experimental and human tumours. such as
cervical carcinoma and melanoma, in which cis-diammine-
dichloroplatinum II (CDDP) is also a treatment of choice
(Bellet et al.. 1978: Stehman et al.. 1989). As DBD and
CDDP have different organ toxicities. clinical trial of these
two drugs in combination therapy is already under considera-
tion. The aim of the present study was to evaluate the
efficacy of CDDP + DBD treatment both in vivo and in vitro.
The combined action of these two drugs was investigated in
mice bearing P388 solid lymphomas and in a metastatic
human melanoma xenograft model transplanted either sub-
cutaneously or intrasplenically.
Since oxygen and nutrient supplies are often limited in
malignant tumours and can influence the therapeutic res-
ponse, including in cervical carcinoma and melanoma, both
of which are sensitive to DBD, the differential cytotoxic
potential of DBD and CDDP against normoxic and hypoxic
tumour cells was investigated. In Chinese hamster V79 multi-
cell spheroids, CDDP exhibited less activity against cells in
the nutrient-deprived and hypoxic regions of the spheroids
than in the external cells (Durand, 1986). Since preliminary
experiments showed that DBD had essentially the opposite
activity, it was naturally of interest to evaluate DBD in
combination with cisplatin at various depths within the
spheroids using cell sorting techniques (Durand, 1982).
To test the possibility that DBD or one of its solvolytic
products, i.e. 1,2:5,6-dianhydro-dulcitol (DAD) or 1-bromo-
1-deoxy-3-6-anhydro-DL dulcitol (BAD), preferentially
attacked other base sequences than CDDP, changes of
cleavage of plasmid DNA by restriction nucleases were
studied. In addition, the DNA interstrand cross-linking
ability of DBD and CDDP was also determined.
Materials and methods
Chemicals
DBD. DAD and BAD were synthesised and subjected to
quality control in the Chinoin Pharmaceutical and Chemical
Works (Budapest, Hungary). CDDP was purchased either
from Lachema (Platidiam) (Brno. Czech Republic) or from
Bristol-Myers-Squibb (Platinol) (Candiac. Quebec. Canada).
Bluescript M13 plasmid was purchased from Stratagene (La
Jolla, CA, USA). BamHI, Sma and EcoRI restriction
nucleases were from Amersham (UK). All chemicals and
reagents were of analytical grade.
Animal studies
All animals (DBA2 x C57BL F, hybrid or CBA male mice
from our breeding unit) in a single experiment were
inoculated with a similar number or mass of a precisely
measured tumour sample. For each experimental group ten
male mice (20-24 g) were kept in a plastic cage. Food (LATI
G6odllo, Hungary) and tap water were given ad libitum and
the temperature and humidity of the animal room were kept
constant.
P388 lymphoma cells (06) were transplanted subcutan-
eously into the hind limb of DBA, x C57BL F, male hybrid
mice. DBD was suspended in 0.5% Tween 80 (Serva, Heidel-
berg, Germany) and CDDP dissolved in saline. Drug treat-
ments were performed i.p. on the fifth day after transplanta-
tion at the doses indicated in the Results section. For com-
bined treatments the second drug was always administered
24 h later. The prolongation of survival time after CDDP-
+ DBD treatment was investigated in three experiments and
the drug action was expressed as increase in lifespan (ILS
The HT-168 human melanoma xenografts were transplant-
ed subcutaneously or into the spleen of immunosuppressed
CBA male mice as reported previously (Ladanyi et al., 1990).
DBD (3 x 250 mg kg-' i.p.) and CDDP (3 x 5 mg kg-' i.p.)
treatments were performed 3, 10 and 14 days after tumour
transplantation, again with a 24 h interval between the
administration of DBD and CDDP for each sequence. The
growth of the tumours was determined at the indicated time
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after transplantation by volume changes. The tumour
volumes (V) were calculated according to the formula
V =n AB2,6. where A is the greatest diameter and B the
diameter at peripendicular to A. The tumour volume at any
time 't' (V,) was compared with the volume of the inoculated
tumour (V.). Mean V,Vo (± s.d.) for each group was plotted
as a function of time to obtain growth curves and the
doubling time of the tumour growth calculated as described
by Jones et al. (1990). In the spleen-liver system, the number
and volume of the metastatic nodules were calculated after
fixation of the liver in Dubosque-Brasil-Bouin (DBB)
fixative 29 days after transplantation. Animals were weighed
concurrently with tumour measurements and the mean
weight (± s.d.) of each group expressed as the percentage
change in the starting weight. In one experiment to reduce
the renal toxic action of CDDP 0.5 ml of physiological saline
was administered i.p. 30 min before and after CDDP treat-
ment.
C}vtotoxicitr measurements on spheroids
V79 Chinese hamster cells were grown in tissue culture as
spheroids as previously described (Durand. 1986). For
evaluating selected populations of viable cells from different
depths within spheroids. a cell sorter-based technique was
applied. Briefly. spheroids exposed to the test compounds for
1 h were stained by adding 2 jiM Hoechst 33342 for 20 min
prior to spheroid disaggregation. After removing excess drug
and stain the spheroids were reduced to a single-cell popula-
tion by using 0.25% trypsin (37C. 10 min). Cell separation
was accomplished with the use of a Becton Dickinson FACS
440. equipped with dual-argon lasers. Ten populations each
comprising 10% of the cells were sorted on the basis of the
slow penetration and rapid binding of the non-toxic fluores-
cent dye Hoechst 33342. The clonogenicity of each recovered
cell population was determined, thus producing a 'chemosen-
sitivity profile' through the entire spheroid (Durand, 1982.
1986). After the analysis of the effects of the two agent
treatments. the observed and the expected survival curves
were plotted as described previously (Durand. 1990).
Measurements on DNA damage
The direct DNA-damaging action of the compounds was
investigated by measuring the cleavability of plasmid DNA
by restriction nucleases and also by the demonstration of
interstrand cross-links (Calcuccia et al.. 1991; Hartley et al..
1991). Bluescript Ml13 plasmid DNA (1 fig) in 20 jl of TEA
buffer (70 mm TRIS + 2 mM EDTA adjusted to pH 8 with
acetic acid) was incubated with the test compounds (dis-
solved in TEA buffer) at 37°C for I h. From the series of
concentrations applied previously in these studies 0.3 giM
CDDP and 3.3 juM DBD or its solvolytic products (DAD.
BAD) were selected as most relevant in terms of plasma
concentration and intermediate activity. Desalting and drug
removal were performed by using an ultrafree MC Millipore
filter. and then 2 units of restriction nuclease was added to
cleave DNA at specific base sequences. BamHI nuclease
selectively cleaves G GATCC. whereas the Smna nuclease acts
on CCC/GGG and EcoRI on G AATT base sequences. The
optimum pH was found to be 7.4 and 6.8 for digestion with
BamHI and Sma respectively. After the 2 h digestion period
the samples were mixed with the loading buffer (0.25%
bromophenol blue. 40% sucrose, 50 mM EDTA, 40 mM Tris
acetate pH 7.5). The restriction fragments were separated by
horizontal electrophoresis using 0.8% (w v) agarose gel con-
taining 1 jLg ml-' ethidium bromide in 40 mM Tris-acetate-
1 mM EDTA (pH 8.0) at 80 V for 4 h. The changes in the
mobility of the digested plasmid DNA indicated nuclease
activity and the resulting fragments were expressed as a
percentage of the supercoiled form. To determine interstrand
cross-links, the bluescript M13 plasmid DNA was linearised
by digestion with BamHI and treated with the test com-
pounds as described above. After removal of the test com-
pounds by using an MC Millipore filter, the DNA samples
were denatured (90°C for 2 min) and chilled in an ice-water
bath prior to loading on 0.8% (w v) agarose gels to separate
single-and double-stranded DNA. This method was based on
the one introduced by Hartley et al. (1991) with the exception
that non-labelled DNA was used and changes in the percen-
tage of the single-stranded DNA were recorded. The DNA
bands were visualised under illumination from a short-wave
UV light and were photographed with a Polaroid camera.
The developed negatives were scanned with a UV-visible
densitometer supported by software for densitogram analysis
(Electrophoretic Data Center. Helena. USA).
Statistical analtsis
Significant differences between control and treatment (DBD.
CDDP) values were determined using a two-tailed t-test.
Differences between means giving a probability of less than
5% were considered as significant (i.e. P<0.05). The com-
bination index (CI) for two drugs were calculated by using a
multiple drug-effect analysis (program B) introduced by
Chou and Talalay (1984) and kindly provided by Dr J
Hoffman (University of Innsbruck, Austria). According to
this analysis the CI is the ratio of the combination dose to
the sum of the isoeffective single agent doses, consequently
CI <1 indicates synergism and CI> 1 indicates
antagonism.
Results
Mice bearing P388 solid lymphomas had a survival time of
12 ± 1.6 days after transplantation. Treatment at an
advanced stage of tumour growth, i.e. 5 days after transplan-
tation, with CDDP or DBD alone induced modest prolonga-
tion of the survival time (Figure 1). However the combined
application of CDDP and DBD resulted in a further prolon-
gation of the survival time compared with animals treated
with either of the drugs alone. Figure 1 shows that, when
using 7 mg kg-' CDDP. the survival time was especially
augmented by both the low (80 mg kg-') and the high
(750 mg kg-') doses of DBD. The combination index (CI) of
Chou and Talalay (1984) varied with the doses of DBD.
Analysing the effect of 80 mg kg-' DBD. the CI values were
less than 1 if 3 or 7 mg kg-' CDDP was administered (0.78
and 0.23 respectively). It is noteworthy that 80 mg kg-' DBD
with 1 or 9 mg kg-' CDDP resulted in antagonistic action
(Cl 1.2 and 1.9 respectively). On the other hand, administer-
ing 750 mg kg-' DBD jointly with 1. 3, 7 or 9 mg kg-'
CDDP induced CI indexes indicating synergism (i.e. 0.8,
0.29, 0.05 and 0.69 respectively). In these mice there was no
indication of increased lethality owing to toxicity; in fact
40% cure (alive 60 days after transplantation) was observed
-j
CDDP (mg kg-')
F_igre I Anti-tumour activity of CDDP against P388 solid lym-
phomas after pretreatment with DBD. Mice were transplanted
subcutaneously with 106 P388 lymphoma cells then treated with
DBD on day 5 and CDDP on day 6 after transplantation. Each
group was composed of ten mice (DBA2 x C57BL, F, hybrid).
Error bars ±s.d. *, CDDP alone; 0 CDDP + DBD 80 mg
kg- ; ., CDDP + DBD 750 mg kg-'.
318after the administration of 750 mg kg-' DBD and 7mgkg-'
CDDP.
Figure 2 shows that tumour volumes for subcutaneous
xenografts of HT168 human melanoma after the combined
treatment with CDDP and DBD were significantly reduced.
The doubling time changes also indicated the greater anti-
tumour action of this combination relative to CDDP or
DBD alone; the value for the untreated tumour was 6.2 days,
which was prolonged to 9.0, 13.1 and 20.7 days in the
CDDP- DBD- and CDDP + DBD-treated experimental groups
respectively.
In another series of experiments, the effects of this com-
bination on metastasis formation from the same tumour
transplanted into the spleen were investigated (Table I).
Notably, the number of metastatic nodules was 86% higher
after CDDP treatment compared with the control value.
Most interestingly, this adverse response to CDDP was
abolished if DBD was administered, especially if CDDP was
given first and then DBD. Conversely, the total volume of all
metastatic nodules per liver was a lower level in all drug-
treated groups. This implies that, while the cellular growth
rate in the metastatic nodules could be reduced, the actual
number of tumour cells seeding the liver was unaffected by
single-agent treatment. The observation that the combined
application of CDDP followed by DBD reduced both the
number and the volume of the metastatic nodules thus
appears quite significant.
Unfortunately, the combined action of CDDP + DBD
caused a significant reduction in body-weight (Figure 3). To
avoid host toxicity the mice were hydrated 30 min before and
30 min after CDDP treatment by administering 0.5 ml of
0.9% sodium chloride. Figure 3 shows that no extreme loss
of body weight was observed in the hydrated mice after
CDDP + DBD treatment, indicating that toxic action of the
combination could be reduced.
As in previous reports, the external cycling cells of the V79
spheroids were most sensitive to CDDP, with less cytotox-
icity at greater depths within the spheroids (Figure 4). These
studies provide the first indication that DBD action is
qualitatively different from that of CDDP, as can be clearly
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seen from the differing sensitivity proffles in Figure 4. Inter-
estingly, DBD decreased the clonogenic capacity of the inter-
nal cells more extensively than those cells of the external
region. suggesting a potential role of hypoxia in modulating
DBD activity. The combined application of DBD and CDDP
resulted in more cytotoxicity; the response was apparently
more than additive (Figure 4a and b).
As both DBD and CDDP have the capacity to bind and
damage DNA, an obvious question is whether synergism can
also be observed at the molecular level, or whether other
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HT-168 melanoma-bearing mice after treatment with CDDP +
DBD. Experimental groups were composed of ten mice as des-
cribed in the Materials and methods section. 0, Controls; 0,
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Fugwe 2 Changes in the tumour volumes of HT-168 human
melanomas after treatment with CDDP and DBD. There were
ten CBA mice in each experimental group. Measurements of
tumour size were performed as described in the Materials and
methods section. 0, Controls; *, CDDP-, 0, DBD-, *, CDDP +
DBD; A, DBD + CDDP.
Fige 4 Survival ofspheroid cells exposed to CDDP and DBD,
shown as a function of cell location in the spheroid at the time of
treatment. a, 0, CDDP Iltgml-; 0, DBD l0jLgml'I; +,
combination expected; *, combination observed; b, 0, CDDP
2tgmlI-; 0, DBD 20jLgml-1; +, combination expected; *,
combination observed.
Table I Effect ofDBD+CDDPcombination on metastatic formation ofHT-168 melanoma. Spleen-livermodel evaluated
at the 29th day after transplantation
Control CDDP DBD CDDP+DBD DBD+CDDP
Number of metastatic nodules 6.61 ± 7.95 12.33 ± 24.8 6.51±9.27 3.29± 5.62 6.29± 5.62
and range (0-25) (0-17) (0-29) (0- 1) (1-16)
Volume of metastatic nodules 39.64±56.85 18.87 ± 26.9 25.27±27.06 2.45±3.73a 10.61 ± 10.12
(mm3)
Body weight (g) 24.23±2.0 21.81 ± 1.27 21.86±2.61 17.12±3.02 19.74± 1.71
Treatments were camred out as described in the Materials and methods. aIndicates significant change from control value.
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Table II Modification ofnucleasedigestion ofbluescript M13 plasmid
DNA treatment with CDDP alone or in combination with DBD. DAD
or BAD
Cleaved plasmid DNA as a percentage of the
supercoiled form
BamHI digestion at
Treatment pH 7.4 Sma digestion at pH 6.8
Controla 97.21±0.81 %.30± 6.35
CDDP (0.3 gAm) 58.95 5.69 47.97±4.79
DBD (3.3 gmM) 88.22 3.71 86.35± 5.02
DAD (3.3MLm) 79.81± 3.80 54.00±2.96
BAD (3.3 gm) 101.40± 1.70 96.65± 0.63
CDDP + DBD 98.33±6.28 51.47±0.57
CDDP + DAD 95.86± 1.83 60.94± 1.06
CDDP + BAD 64.70±0.96 103.27±0.38
aBluescript Ml3 plasmid DNA was digested with either BamHI or Sma
as described in the Matenrals and methods section. Data presented are
from a representative experiment. mean±s.d. (n = 2).
of DBD. was more potent. especially if Sma was applied at
pH 6.8. Conversely. BAD. the other solvolytic product of
DBD. was completely inactive. The unique feature of the
action DBD and its metabolites (DAD. BAD) was that in
their presence there was no reduction in the nuclease activity
induced by CDDP. By measuring BamHI nuclease activity.
an apparent antagonism was observed between CDDP +
DBD and CDDP + BAD. whereas BAD affected only the
inhibitory action of CDDP against the Sma digestion (Table
II). Measurements of cross-link formation led to the conc-
lusion that CDDP and DBD treatment induce different types
of DNA damage. as it was shown that CDDP induces cross-
linkage, whereas after DBD treatment formation of single
strand breaks was the dominant change (Figure 5).
a
z
.;e
E
0
0
0C 'c C
b
| CDDP
d
0
CD
0
0 CDDP+
L i~~DB
Electrophoretic mobility of DNA (-_)
Figure 5 Identification of cross-links and single-strand breaks of
DNA. a. Separation of double- and single-stranded DNA on gel
electrophoresis without drug treatment. The first peak shows
double stranded DNA. the second peak represents the greater
mobility of single-stranded DNA. b. The appearance of cross-
linked DNA fragments at the position of double-stranded DNA
after treatment with CDDP (0.3 Mm) and heat denaturation. c.
Appearance of single-strand breaks with smaller fragment size
after DBD treatment (3.3 gM) and heat denaturation. d.
Appearances of both cross-links and single-strand breaks of
DNA after simultaneous treatment with CDDP + DBD and heat
denaturation.
factors might contribute to the enhanced anti-tumour efficacy
upon the combined application of these agents. Since cell-
associated drug metabolism is not a prerequisite step for
either CDDP or DBD action there seemed to be no objection
to using naked DNA to investigate the combined action of
these drugs. The cleavage of bluescript M13 plasmid DNA
induced by BamHI, Sma or EcoRI restriction nucleases was
examined to detect drug binding at specific sites in the DNA.
Digestion with nucleases resulted in a 96-97% conversion of
the plasmid DNA from the supercoiled to the linearised
form. This process was remarkably lower after treating the
DNA with some of the test compounds. Treatment with
0.3 gM CDDP and 3.3pM DBD was shown to prevent cleav-
age of plasmid DNA by approximately 50% and 13%
respectively regardless of whether BamHI or Sma was used
as the restriction nuclease. However, no changes occurred if
DNA was cleaved by EcoRI in the presence of DBD (data
not shown). Interestingly. DAD, the active solvolytic product
The results reported here suggest that the anti-tumour
efficacy of DBD and cisplatim in combination is greater than
the efficacy of a single application of either drug alone in a
human metastatic tumour model and in mice bearing solid
P388 lymphomas. In the latter model a remarkable increase
in the survival time was also observed.
The biological changes induced by the combined applica-
tion of DBD + CDDP showed certain qualitative differences
from the action of either drug alone. This was apparent in
the human metastatic model (HT-168 melanoma) in which
DBD was not effective and CDDP increased the number and
decreased the volume of the metastatic nodules (Table II). It
is noteworthy that the combined use of the two drugs
resulted in a significant reduction in both the number and
volume of the metastatic nodules. This raised the question of
whether greater anti-tumour efficacy of this combination
could develop at a cell population or at a molecular level.
Investigation using the V79 spheroids led to the conclusion
that cells located at the external and internal regions of the
spheroids show different sensitivity to DBD and CDDP.
Studies on plasmid DNA showed that DBD treatment causes
primarily single-strand breaks. whereas cross-links are
formed after CDDP treatment. The two drugs acted synergis-
tically in the production of strand breaks. but the number of
CDDP-induced cross-links was reduced in the presence of
DBD. Drug antagonism in this model system may be due to
the solvolytic metabolites of DBD. because the mecham'sm of
action of DAD and BAD in reversing the effect of CDDP
was different in the BamHI and Sma nuclease assays, and in
the latter assay system DBD showed no interference in
CDDP action. These findings may be an explanation for the
dose-dependent synergism between DBD and CDDP if one
considers the possibility that the ratio of the metabolites
generated from DBD is dose dependent (Figure 1). The
formation of BAD and DAD from DBD was characterised
as solvolysis and both compounds were identified both in the
plasma of patients treated with DBD and in a cell-free
system (Horvath et al., 1979. 1982; Vidra et al.. 1982; Kelley
et al., 1986). It is conceivable that DBD + CDDP synergism
may be determined by the type and concentration of DBD
metabolites.
In the last few years, more emphasis has been placed on
drug activity in hypoxic tumour cells, and several methods of
killing hypoxic tumour cells are currently being investigated
(Sartorelli. 1988). Numerous new chemical entities have been
designed which have no reactive capacity unless they are
activated by bioreductive processes under hypoxic conditions
(Sartorelli, 1988; Walton et al., 1989). Often, the cytotoxic
action of such agents can be augmented through manipula-
tion of blood flow (Brown. 1991). Since DBD appears to be
preferentially active against hypoxic cells in spheroids at
therapeutically relevant doses, though with much lower
oxygen-dependent specificity than many other bioreductive
drugs, it may find application in combination with cisplatin
as well as other drugs not effective against hypoxic cell
subpopulations. Certainly the internal cells in the spheroids
have other characteristic features, such as adaptation to the
320
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hypoxic surroundings. Enlargement of spheroids is accom-
panied by changes in ploidy and in extracellular matrix
constituents and by a decrease in extracellular pH (Olive and
Durand. 1994). Consequently. factors other than hypoxia
could determine the higher efficacy of DBD against the cells
located at the internal region of the spheroid.
In addition to the complementary toxicity patterns for
DBD and CDDP. our data also suggest synergistic inter-
actions at the tumour, cellular and DNA levels. The marked
increase in DNA strand break production by combination
treatments is notable, as is the apparent 'antagonism' of the
drugs in some cleavage assays. The latter results presumably
indicate a qualitative difference in the molecular lesions
formed, a result not incompatible with synergistic cytotox-
icity. These observations clearly require additional study.
In summary, dibromodulcitol appears to be a promising
new chemotherapeutic agent owing to its preferential toxicity
towards hypoxic cells in vitro. This utility is amplified by the
observed synergism with cisplatin. and suggests that DBD
may also prove efficacious in combination with a number of
other conventional cancer chemotherapy agents.
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